Accessibility Statement Skip Navigation
  • PRNewswire.com
  • Resources
  • +91 22-69790010
  • Client Login
  • Send a Release
PR Newswire: news distribution, targeting and monitoring
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please use Advanced Search to search all press releases.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
    • Business & Money
        • Auto & Transportation

        • Aerospace & Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads & Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking & Road Transportation
        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film & Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers & Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalisation
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls & Research
        • Trade Show News
        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil & Gas Discoveries
        • Utilities
        • Water Utilities
        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defence
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation & Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking & Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers & Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines & Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics & Personal Care
        • Fashion
        • Food & Beverages
        • Furniture & Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewellery
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film & Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • View All Sports

        • Travel

        • Amusement Parks & Tourist Attractions
        • Gambling & Casinos
        • Hotels & Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Animal Welfare
        • Corporate Social Responsibility
        • Economic News, Trends & Analysis
        • Education
        • Environmental
        • European Government
        • Labour & Union
        • Natural Disasters
        • Not For Profit
        • Public Safety
        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • Telephone

      • +91 22-69790010 from 9 AM - 5:30 PM IST

      • Contact
      • Contact

        +91 22-69790010
        from 9 AM - 5:30 PM IST

    Close menu
  • News
  • Products
  • Contact
    • Request More Information
    • Journalists
    • 2 News in Focus
    • 5 Business & Money
    • 5 Science & Tech
    • 5 Lifestyle & Health
    • 1 Policy & Public Interest
    • 1 People & Culture
    • Request More Information
    • Journalists
    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • Request More Information
    • Journalists
    • General Inquiries
    • Worldwide Offices
    • Request More Information
    • Journalists
    Close submenu (News in Focus) News in Focus
    • Browse News Releases
    • Multimedia Gallery
    Close submenu (Business & Money) Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
    Close submenu (Science & Tech) Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
    Close submenu (Lifestyle & Health) Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
    Close submenu (Policy & Public Interest) Policy & Public Interest
    • Policy & Public Interest
    Close submenu (People & Culture) People & Culture
    • People & Culture

    Ozempic® Offers Superior Reductions in HbA1c and Body Weight Compared to Both Victoza® and Canagliflozin in People With Type 2 Diabetes


    17 Sep, 2019, 19:15 IST

    Share this article

    Share this article


    BAGSVÆRD, Denmark, Sept. 17, 2019 /PRNewswire/ -- Novo Nordisk announced today the results from two Ozempic® (once-weekly semaglutide 1.0 mg) head-to-head Phase 3 clinical trials, SUSTAIN 8 and SUSTAIN 10, which showed:

    • Ozempic® was superior to treatment with the SGLT-2 inhibitor canagliflozin (300 mg) in reducing HbA1c and body weight in people with type 2 diabetes uncontrolled on metformin.1
    • Ozempic® was superior to Victoza® (liraglutide 1.2 mg) in reducing HbA1c and body weight in people with type 2 diabetes.2

    These data were presented at the European Association for the Study of Diabetes (EASD) Annual Meeting in Barcelona, and simultaneously published in The Lancet Diabetes & Endocrinology (SUSTAIN 8) and Diabetes and Metabolism (SUSTAIN 10).1,2

    "We are proud of the superior clinical profile of once-weekly Ozempic®, as demonstrated through all the SUSTAIN clinical trials, and encouraged by these new data which further reinforce the value of Ozempic® for people with type 2 diabetes," said Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk.

    These trials form part of the extensive SUSTAIN programme, a global clinical development programme that comprises more than 10 Phase 3 trials involving more than 10,065 adults with type 2 diabetes. To date, outcomes of SUSTAIN 1-7 and 9 have been published demonstrating Ozempic® is a best-in-class, efficacious and well-tolerated treatment option for people with type 2 diabetes.

    SUSTAIN 81

    At 52 weeks, Ozempic® demonstrated a superior reduction in mean HbA1c of 1.5% compared to canagliflozin at 1.0%, from a baseline of 8.3%. In addition, 66.1% of people treated with Ozempic® achieved HbA1c treatment target <7% vs 45.1% of those treated with canagliflozin. People treated with Ozempic® also demonstrated superior reductions in body weight compared with canagliflozin with 5.3 kg vs 4.2 kg, respectively, from a mean baseline of 90.2 kg. Significantly more people treated with Ozempic® achieved reduction in body weight of ≥10% vs canagliflozin (22.3% vs 8.9%, respectively).

    "To date, head-to-head trials of GLP-1 receptor agonists and SGLT-2 inhibitors have been limited," said Dr Ildiko Lingvay, University of Texas Southwestern Medical Centre, Dallas, and lead study investigator. "These data seen in the SUSTAIN 8 trial support Ozempic® as an efficacious treatment option for reducing blood sugar and body weight for people with type 2 diabetes after metformin."

    SUSTAIN 102

    At 30 weeks, Ozempic® demonstrated a superior reduction in mean HbA1c compared to Victoza® (1.7% vs 1.0% respectively), from a mean baseline of 8.2%. In addition, 80% of people treated with Ozempic® achieved HbA1c treatment target of <7% vs 46% of those treated with Victoza®. People treated with Ozempic® also demonstrated superior reductions in body weight compared with Victoza® with 5.8 kg vs 1.9 kg, respectively, from a mean baseline of 96.9 kg. Significantly more people treated with Ozempic® achieved reduction in body weight of ≥10% than those treated with Victoza® (19% vs 4%, respectively).

    "Intensifying treatment with Ozempic® showed significant benefits over Victoza® in terms of blood sugar control and reduction in body weight, providing an alternative treatment option for those uncontrolled on current treatment," said Dr Matthew Capehorn, Rotherham Institute for Obesity, UK, and lead study investigator.

    The tolerability of once-weekly Ozempic® was generally similar to that of Victoza® and canagliflozin, except for higher rates of gastrointestinal adverse events (AEs) with Ozempic® vs Victoza® and more frequent infections and infestations with canagliflozin vs Ozempic®. The safety profile of Ozempic® 1.0 mg in both trials was consistent with the overall SUSTAIN clinical trial programme.

    About Ozempic®

    Once-weekly Ozempic® (semaglutide) is an analogue of human glucagon-like peptide-1 (GLP-1) indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes.3,4 Ozempic® was first approved by the US FDA in 2017 and is now launched in 25 countries.

    About SUSTAIN 8

    SUSTAIN 8 is a 52-week double-blinded Phase 3 trial investigating the efficacy and safety of once-weekly Ozempic® (semaglutide 1.0 mg) vs canagliflozin 300 mg as add-on to metformin in people with type 2 diabetes. The primary endpoint was change in HbA1c from baseline to Week 52, and key secondary endpoints include change in body weight at Week 52 and proportion of people achieving HbA1c <7.0% (53 mmol/mol) at Week 52.1

    About SUSTAIN 10

    SUSTAIN 10 is a 30-week open-label Phase 3b trial investigating the safety and efficacy of Ozempic® 1.0 mg once-weekly vs Victoza® 1.2 mg once-daily, as add-on to 1–3 oral antidiabetics (OADs) in 577 adults with type 2 diabetes in Europe. The primary endpoint was change in HbA1c at Week 30, and key secondary endpoints include change in body weight at Week 30 and proportion of people achieving HbA1c <7.0% (53 mmol/mol) at Week 30.2

    About Novo Nordisk 

    Novo Nordisk is a global healthcare company with more than 95 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat obesity, haemophilia, growth disorders and other serious chronic diseases. Headquartered in Denmark, Novo Nordisk employs approximately 41,600 people in 80 countries and markets its products in more than 170 countries. For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube.

    References

    1. Lingvay I, et al. Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, randomised, controlled trial. The Lancet Diabetes & Endocrinology. Published Online 17 September 2019. http://dx.doi.org/10.1016/PII 
    2. Capehorn MS, et al. Efficacy and safety of once-weekly semaglutide 1.0 mg vs once-daily liraglutide 1.2 mg as add-on to 1–3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10). Diabetes Metab (2019). https://doi.org/10.1016/j.diabet.2019.101117
    3. EMA. Ozempic® Summary of Product Characteristics. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/004174/WC500244163.pdf. Last accessed: September 2019. 
    4. FDA. Ozempic® US Prescribing Information. December 2017. Available at: http://www.novo-pi.com/ozempic.pdf Last accessed: September 2019. 

    Further information

    Media:



    Mette Kruse Danielsen

    +45 3079 3883

    [email protected]

    Ken Inchausti (US)

    +1 609 240 9429

    [email protected] 

    Investors:



    Peter Hugreffe Ankersen

    +45 3075 9085

    [email protected]

    Kristoffer Due Berg (US)

    +1 609 235 2989

    [email protected]

    Valdemar Borum Svarrer

    +45 3079 0301

    [email protected] 

    Ann Søndermølle Rendbæk                  

    +45 3075 2253

    [email protected] 

    Modal title

    Contact PR Newswire

    • +91 22-69790010

    Global Sites

    • APAC
    • APAC - Traditional Chinese
    • Asia
    • Brazil
    • Canada
    • Czech
    • Denmark
    • Finland
    • France
    • Germany

     

    • India
    • Indonesia
    • Israel
    • Italy
    • Mexico
    • Middle East
    • Middle East - Arabic
    • Netherlands
    • Norway
    • Poland

     

    • Portugal
    • Russia
    • Slovakia
    • Spain
    • Sweden
    • United Kingdom
    • United States

    Do not sell or share my personal information:

    • Submit via [email protected] 
    • Call Privacy toll-free: 877-297-8921
    Global Sites
    • Asia
    • Brazil
    • Canada
    • Czech
    • Denmark
    • Finland
    • France
    • Germany
    • India
    • Israel
    • Italy
    • Mexico
    • Middle East
    • Netherlands
    • Norway
    • Poland
    • Portugal
    • Russia
    • Slovakia
    • Spain
    • Sweden
    • United Kingdom
    • United States
    +91 (0) 22 6169 6000
    from 9 AM - 5:30 PM IST
    • Terms of Use
    • Privacy Policy
    • GDPR
    • Information Security Policy
    • Site Map
    • Cookie Settings
    Copyright © 2026 Cision US Inc.